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terminologies used for thyroid FNA throughout the world. 
The TBSRTC consists of 6 diagnostic categories, each asso-
ciated with an implied risk of malignancy that translates
directly into a clinical management algorithm. Since the 
publication of the TBSRTC cytology Atlas in January 2010, 
considerable experience has been gained regarding its ap-
plication in cytology practice, clinical impact, and limita-
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 Abstract 
The Bethesda System for Reporting Thyroid Cytology (TB-
SRTC) was proposed in 2007 at the National Cancer Institute 
Thyroid Fine Needle Aspiration State of the Art and Science 
Conference held in Bethesda, Maryland. The aim was to ad-
dress the inconsistent and sometimes confusing reporting 
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tions. In conjunction with the International Academy of Cy-
tology (IAC), an international panel composed of sixteen cy-
topathologists and an endocrinologist with special interest 
in thyroid cytology, including several co-authors of the 2010 
TBSRTC Atlas, was created to: (1) analyze the current world-
wide impact of TBSRTC, (2) report on the current state of
TBSRTC based upon a review of the published literature, and 
(3) provide possible recommendations for a future update of 
TBSRTC. Herein, we summarize the panel’s deliberations and 
key recommendations that our panel hopes will be useful 
during the preparation of the second edition of TBSRTC . 
 © 2016 S. Karger AG, Basel 
 Introduction 
 The introduction of The Bethesda System for Report-
ing Thyroid Cytopathology (TBSRTC), following the 
“National Cancer Institute Thyroid Fine Needle Aspira-
tion State of the Science Conference” held in Bethesda, 
MD, in 2007, offered the opportunity to establish a uni-
form six-tiered reporting system for thyroid FNA  [1] . The 
TBSRTC not only included the diagnostic designations 
for the commonly encountered benign and malignant 
thyroid lesions in FNA specimens but also for those that 
are often diagnosed as “indeterminate for malignancy 
(the so-called ‘grey zone’)”  [1] . The latter were sub-clas-
sified into the diagnostic categories of: (i) Atypia of unde-
termined significance (AUS)/Follicular lesion of undeter-
mined significance (FLUS); (ii) Follicular neoplasm (FN)/
Suspicious for a follicular neoplasm (SFN) and (iii) Suspi-
cious for malignancy (SM). For each of the diagnostic cat-
egories, TBSRTC defined an implied risk of malignancy 
(ROM) based upon the data from the available literature; 
and clinical management scenario(s)  [1] .
 Over the past seven years, TBSRTC has found wide-
spread international acceptance, and has contributed sig-
nificantly to the management of thyroid nodules by in-
creasing the quality and reproducibility of thyroid cytol-
ogy reporting  [2, 3] . Moreover, the use of TBSRTC has 
been endorsed by the American Thyroid Association 
(ATA) as part of the revised 2015 ATA guidelines  [4] .
 In light of the recent advances and developments in the 
field of thyroid disease, a second edition of TBSRTC, 
scheduled to be released in 2018, seems appropriate.  In 
anticipation of the latter, Drs. Syed Ali, Edmund Cibas 
and Philippe Viehl proposed the formation of an interna-
tional panel of cytopathologists, pathologists and an en-
docrine surgeon to assess the available literature and pro-
pose useful modifications to TBSRTC. The topics to be 
addressed would include cytomorphological criteria for 
FNA classification, reporting terminology, implied ROM 
for each diagnostic category, and the anticipated changes 
due to the recently described non-invasive follicular
thyroid neoplasm with papillary-like nuclear features 
(NIFTP)  [5, 6] . The summary of this effort and the panel 
recommendations were presented in a Symposium en-
titled “TBSRTC: Past, Present, and Future” moderated by 
Drs. Ali and Vielh at the 2016 ICC meeting held in Yoko-
hama, Japan. Herein, we summarize the panel’s delibera-
tions and key recommendations that our panel hopes will 
be useful during the preparation of the second edition of 
TBSRTC.  
 Selected General Issues of TBSRTC  
 Reporting of Specific Uncommon Non-Thyroid 
Entities in TBSRTC  
 TBSRTC was designed specifically for the reporting of 
thyroid follicular and C-cell-derived lesions. On occa-
sion, an FNA will be performed of a non-thyroid entity 
presenting as a thyroid nodule, the most common be-
ing an enlarged parathyroid secondary to hyperplasia or 
neoplasia. Other potential lesions include intrathyroidal 
paragangliomas, Langerhans cell histiocytosis, solitary fi-
brous tumor, and rare mesenchymal tumors. For such 
cases where specific classification is possible, our panel 
does not recommend creation of a separate diagnostic 
category within TBSRTC for these uncommon lesions of 
non-thyroid origin. Instead, the lesion can be reported 
using traditional cytologic reporting categories. 
 Implied Risk of Malignancy (ROM)  
 Since the introduction of TBSRTC into clinical prac-
tice, numerous studies have contributed to refinement of 
the implied ROM attributed to each of the 6 diagnostic 
categories  [2–4] . Some studies, however, have reported 
inﬂated ROMs particularly in the indeterminate diagnos-
tic categories, that are inﬂuenced by case selection, partial 
verification, and publication biases  [7] . Our panel recom-
mends adjustments to the implied ROM in TBSRTC based 
upon a selected group of studies that included large co-
horts of cases or meta-analyses  [2, 3] . Such modifications 
could be provided as an update to Table  1 .2 in the Atlas. 
 Non Invasive Follicular Thyroid Neoplasm with 
Papillary-Like Nuclear Features (NIFTP)  
 The introduction of NIFTP  [5, 6] , presents a challenge 
for thyroid cytology. Recent studies indicate that a major-
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ity of NIFTP cases are sequestered within the indetermi-
nate categories of TBSRTC leading to a significant impact 
on the implied ROM  [8–11] . It remains to be seen how 
NIFTP will be incorporated into thyroid pathology and 
affect management algorithms. Potential modifications 
to TBSRTC could include adjustments in the ROM asso-
ciated with various diagnostic categories or revision of 
ROM to ‘risk of neoplasm’ to accommodate for NIFTP. 
In addition, for thyroid FNA cases with mild nuclear 
atypia that are borderline between SM and FN/SFN, a 
conservative approach of classifying these FNAs as FN/
SFN could be used. The latter is acceptable since the ini-
tial surgical management of NIFTP and FN would be sim-
ilar  [5] . Some institutions have already established spe-
cific policies regarding thyroid FNA interpretations and 
reporting in the NIFTP era. This includes explanatory 
notes added to the cytologic diagnosis about the possibil-
ity of NIFTP on histologic follow-up. As expected, such 
explanatory notes could be particularly useful for the FN/
SFN, SM, and Malignant categories. 
 Limited retrospective studies have shown that TB-
SRTC is currently effective at identifying potential cases 
of NIFTP and triaging patients for conservative surgical 
excision  [8–11] . A single prospective study by Strickland 
et al. has shown that the presence of a microfollicular ar-
chitecture and absence of papillae, psammomatous calci-
fications, and nuclear pseudoinclusions is helpful in dis-
tinguishing potential NIFTP/FVPTC cases from classical 
PTC in aspirates diagnosed as SM or Malignant  [12] . If 
verified by other investigators, these criteria may aid in 
identifying SM aspirates warranting conservative surgical 
management and in limiting false positive malignant di-
agnoses due to NIFTP. 
 Management Algorithm and the 2015 ATA Guidelines 
 The 2015 revised ATA guidelines endorsed the use of 
TBSRTC, and provide updated recommendations for the 
management of thyroid nodules  [4] . In general, the con-
cept of low-risk versus high-risk disease and the increased 
role of conservative management through the application 
of molecular testing  [13–17] , clinico-radiologic risk strati-
fication, and a multidisciplinary team approach should re-
ceive greater emphasis in TBSRTC. These management 
updates could be incorporated into the various diagnostic 
categories and thyroid entities covered in TBSRTC Atlas. 
 Diagnostic Category Designations 
 TBSRTC includes several categories (ND/UNSAT, 
AUS/FLUS, FN/SFN) where more than one term can be 
used for reporting results of a thyroid FNA  [1] . Ideally, 
only one term would be assigned to each diagnostic cat-
egory; however, it is understood that most laboratories 
have already established the use of one of two terms for 
selected diagnostic categories in their clinical practice. 
Thus, for practical reasons, it would be counterproduc-
tive to eliminate this ﬂexibility in nomenclature. The ap-
plication of TBSRTC terminology, with reasonably ac-
ceptable variations can be maintained as long as there is 
consistency at a given laboratory and good communica-
tion between the different members of the health care 
team. However, it should not open the doors to major 
alterations of the terminology which would defeat the 
purpose of TBSRTC. 
 Quality Control  
 The reporting of thyroid FNA using TBSRTC offers 
the possibility for laboratory monitoring of key parame-
ters, in particular, the over-utilization of the AUS/FLUS 
category  [2, 3] . This can be avoided by intra-laboratory 
monitoring at regular intervals of the rate of AUS/FLUS. 
One study proposed using the AUS/M ratio as a quality 
control measure to accomplish this  [18] . In addition, the 
panel encourages continuous cytologic-histologic corre-
lation for thyroid FNA. 
 Specific Issues Pertaining to the Different Diagnostic 
Categories and Chapters of TBSRTC  
 Non-Diagnostic/Unsatisfactory  
 A specimen is defined as Non-Diagnostic (ND) in TB-
SRTC if it fails to meet the adequacy criteria (i.e., at least 
6 groups, each with at least 10 benign-appearing, well-
visualized follicular cells), with exceptions for thyroiditis, 
“abundant” colloid, or any degree of perceived atypia  [1] . 
It is important to acknowledge that these adequacy crite-
ria are based upon consensus opinion and are not evi-
dence-based. Clarification of the specific adequacy crite-
ria for laboratories using liquid based preparations (LBP) 
(ThinPrep and Surepath) alone or in combination with 
smears is recommended. While some controversy has ex-
isted concerning the reporting of cystic lesions, the panel 
recommends that “Cyst ﬂuid (macrophages) only” cases 
should still be reported as ND with an explanatory note, 
as exemplified in the sample reports of TBSRTC Atlas. 
 The management recommendation for ND samples 
including cystic lesions have been updated in the 2015 
revised ATA guidelines  [4] . In large series of thyroid 
FNAs classified based upon TBSRTC, ND samples con-
stituted 2–16% of all FNA samples, of which 7–26% were 
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eventually resected  [4] . The ROM was 2–4% among all 
initially ND samples and 9–32% among those ND sam-
ples that were resected  [4] . While it was originally recom-
mended to wait >3 months to perform a repeat FNA, ev-
idence exists to support shorter intervals for repeating an 
FNA after a ND result  [4, 19, 20] . However, it should be 
noted that reactive atypia and other cellular changes may 
be present if the time interval is shortened. 
 Benign  
 Several recent studies have confirmed that the ROM
is very low for this category  [4, 21, 22] . Risk stratifica-
tion based upon ultrasound patterns (ATA 2015 revised 
guidelines) can be used to guide clinical follow-up of thy-
roid nodules with benign cytology  [4] . We propose the 
inclusions of more LBP images as well as IgG4 thyroiditis 
for this category in the Second Edition TBSRTC Atlas. 
 AUS/FLUS  
 Several retrospective and prospective studies have 
evaluated the role of the AUS/FLUS category in the man-
agement of thyroid nodules. The panel endorses the AUS/
FLUS category, as it is now widely accepted and is also 
included in the current ATA clinical management guide-
lines  [4] . In addition, the AUS/FLUS category has been 
shown to maintain the sensitivity for detecting thyroid 
neoplasms, with decreased false-negative and false-posi-
tive rates, making thyroid FNA a more effective screening 
test. While our panel would favor the use of a single term 
such as AUS/FLUS for this category, we recognize that the 
most practical approach would be to maintain current 
nomenclature practices. As such, only one term, either 
AUS or FLUS would be selected by a laboratory because 
they are synonymous. 
 Our panel recommends subclassification of AUS/
FLUS, particularly with respect to the presence or absence 
of nuclear atypia. This could be accomplished using a 
concise note, Common patterns that would be candidates 
for subclassifiers include: architectural atypia, nuclear 
atypia, oncocytic features, and NOS. Several studies have 
demonstrated that subclassification within the AUS/
FLUS category can be effective to better define the ROM, 
and that nuclear atypia is associated with a higher ROM 
than other AUS/FLUS patterns  [23–28] .
 In order to limit the overall rate of AUS/FLUS, com-
promised samples lacking significant atypia should be 
classified as ND rather than AUS/FLUS. For the manage-
ment of AUS/FLUS, all clinical, radiologic, pathologic, 
and molecular findings should be integrated for the most 
informed, accurate, and individualized patient assess-
ment (a.k.a. personalized approach). While repeat FNA is 
recommended in the current version of TBSRTC, the re-
vised ATA guidelines recognize molecular testing as a 
valid alternative  [4] .
 Follicular Neoplasm/Suspicious for a Follicular 
Neoplasm  
 As with two other diagnostic categories where a choice 
between two different nomenclature designations is 
available, our panel favors the use of one; however, we 
recognize that for practical reasons, the use of either term 
is acceptable. In addition, there is concern that neither of 
the two nomenclature options for this category is ideal 
because: (1) SFN can be mistaken for SM due to the term 
‘suspicious’ that these two categories share, and (2) FN 
denotes an unjustified certainty about the presence of a 
neoplasm. The alternative use of the term “Suggestive of 
FN” has been proposed by some, as this would connote 
uncertainty regarding neoplasia while also being distinct 
from the SM category. In our opinion, current diagnostic 
criteria for FN/SFN could be further defined to more 
clearly distinguish lesions that would belong in this cat-
egory from those that might be more appropriately 
placed in the AUS/FLUS and SM categories. As men-
tioned above, with the advent of NIFTP, one could con-
sider classifying follicular patterned lesions with nuclear 
atypia as FN/SFN rather than SM. Diagnostic surgical 
excision has been the long-established standard of care 
for the management of FN/SFN; however, the ATA 2015 
guidelines now provide the option of molecular testing 
 [4] .
 Follicular Neoplasm/Suspicious for a Follicular 
Neoplasm, Hürthle Cell Type  
 The use of the term “oncocytic” instead of “Hürthle 
cell” throughout TBSRTC is recommended to align with 
current WHO classification terminology. A rare malig-
nant subset of oncocytic lesions with abundant colloid 
has been described  [29] , and this pitfall should be men-
tioned in TBSRTC. In addition, the accuracy of molecular 
testing may be lower for FNAs of oncocytic lesions. Spe-
cifically, there is an increased rate of “Suspicious” results 
in benign oncocytic lesions using the Afirma gene-ex-
pression classifier  [30–33] .
 Suspicious for Malignancy  
 Poorly differentiated thyroid carcinoma (PDTC) 
should be included among the differential diagnoses in 
the SM category. The utility of molecular testing employ-
ing panels with high positive predictive value is likely to 
D
ow
nl
oa
de
d 
by
: 
Yo
ns
ei
 U
ni
ve
rs
ity
   
   
   
   
   
   
   
   
   
   
   
   
  
12
8.
13
4.
20
7.
84
 - 
12
/2
6/
20
17
 6
:4
6:
05
 A
M
 The Bethesda System for Reporting 
Thyroid Cytopathology 
Acta Cytologica 2016;60:399–405
DOI: 10.1159/000451020
403
be beneficial in the SM category, notably for the detec-
tion of potential NIFTP cases (e.g., RAS, THADA or 
BRAF K601E positive and BRAF V600E negative). According 
to the 2015 ATA guidelines, total thyroidectomy is an 
option for patients with nodules that are cytologically 
SM, positive for known mutations specific for carcinoma 
(BRAF V600E , TERT-Promoter, p53), sonographically 
suspicious, or of large size (>4 cm)  [4]  with the under-
standing that a subset of these may represent NIFTP on 
surgical excision. A comment that NIFTP comprises a 
subset of SM cases is optional for this category. 
 Papillary Thyroid Carcinoma  
 Recent publications have highlighted certain differ-
ences in the cytological features of PTC in LBPs as com-
pared to conventional cytologic preparations  [34, 35] . In 
addition, the cytological features of several variants of 
PTC, such as hobnail, diffuse sclerosing, solid, and crib-
riform-morular variants should be more fully described 
and illustrated in the revised TBSRTC. Although defini-
tive cytologic subclassification as a specific PTC variant is 
not necessary, increasing familiarity with the morpholog-
ic features of PTC variants will decrease the risk of misdi-
agnosis. 
 More detailed descriptions of the FVPTC as men-
tioned previously would be useful as it relates to NIFTP, 
and there may be a role for classifying FVPTC as SM to 
avoid a false positive diagnosis. Updated information 
pertaining to the clinical behavior of FVPTC, especially 
in light of recent TCGA data  [36] , the new NIFTP termi-
nology  [5, 6] , and other clinico-pathological studies is 
needed  [37–39] . Hyalinizing trabecular tumor is now rec-
ognized as a mimic of PTC rather than as a variant of PTC 
per se  [40] .
 Medullary Thyroid Carcinoma  
 MTC accounts for only 1–2% of thyroid cancers in the 
USA, a much lower range than frequently cited (3–5, and 
7% in TBSRTC), primarily due to the marked increase in 
the relative incidence of PTC  [41] . As suggested in the 
2015 ATA Guidelines, the assessment of calcitonin levels 
can be helpful both in the blood and in FNA washout ﬂuid 
for suspected MTC cases, especially when IHC confirma-
tion is not possible (e.g., limited cellularity or equivocal 
IHC results)  [41, 42] . Additional descriptors pertaining 
to rare morphologic variants of MTC (e.g., small cell, gi-
ant cell) that can be diagnostically challenging would be 
useful  [43, 44] . Other diagnostic pitfalls that could be ad-
dressed include: (1) Morphological overlap with onco-
cytic follicular lesions and PDTC  [45] ; and (2) Morpho-
logical and immunohistochemical overlap with other 
neuroendocrine tumors  [46] . In addition, some aspects of 
the management of MTC have been updated in the 2015 
revised ATA guidelines  [41] .
 Poorly Differentiated Thyroid Carcinoma (PDTC)  
 As mentioned above, a subset of PDTC will be diag-
nosed as SM, and in some cases PDTC can be a diagnostic 
pitfall for MTC. Additionally, an oncocytic variant of 
PDTC has been recently described  [47] . Some advances 
have been made in the molecular characterization of 
PDTC, including TERT mutations and microRNA signa-
tures; however, these molecular features are not specific 
for PDTC and therefore have limited use in routine prac-
tice. 
 Undifferentiated (Anaplastic) Carcinoma (UTC) and 
Squamous Cell Carcinoma of the Thyroid  
 There is a potential role of ICC to confirm UTC. PAX-
8 is a helpful immunocytochemical stain  [48–50] , since it 
is usually retained in UTC, while TTF-1 can rarely be fo-
cal and variably positive, and thyroglobulin is always neg-
ative. Some advances have been made in the molecular 
characterization of UTC, including high rates of MAPK 
pathway genes mutations, p53 mutations, and TERT–
promoter mutations. However, the clinical management 
and the prognosis of UTC or primary squamous cell car-
cinoma have not changed significantly. 
 Metastases and Lymphomas  
 TBSRTC defines the diagnostic criteria and provides 
explanatory notes for some of the most common meta-
static cancers; the latter could be expanded to include oth-
ers such as metastatic neuroendocrine tumors. Several
recent FNA studies on secondary thyroid malignancies 
have emphasized the important role of clinical history 
and the judicious use of immunomarkers (limited mostly 
to cases with adequate cellularity) to increase the sensitiv-
ity and accuracy of FNA for detecting metastases  [51, 52] . 
An expanded array of useful immunocytochemical mark-
ers, including PAX-8 and GATA-3 are available. In addi-
tion, information on the clinical management of meta-
static disease and lymphomas is needed. 
 Conclusions  
 The launch of TBSRTC in January 2010 proved to be 
very successful, and TBSRTC is now the most common 
classification worldwide for the reporting of thyroid FNA 
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specimens. Since its inception, additional knowledge and 
experience pertaining to various aspects of thyroid FNA 
have been obtained. In view of this, and in anticipation of 
the second edition of TBSRTC in 2018, our panel has pro-
vided its suggestions which we hope will prove useful for 
the second edition covering various aspects of thyroid 
FNA including nomenclature, differential diagnosis, the 
potential impact of NIFTP on the indeterminate diagnos-
tic categories, utility of molecular and IHC markers, and 
clinical management.
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